600594.SH
益佰制药
SSE · Healthcare · Drug Manufacturers - Specialty & Generic · CN
CNY 4.09
+9.95%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 1.7B | 1.9B | 2.2B | 2.8B | 2.7B |
| Cost of Revenue | 702.7M | 751.5M | 829.4M | 861.1M | 794.2M |
| Gross Profit | 1.0B | 1.1B | 1.3B | 2.0B | 1.9B |
| Operating Expenses | |||||
| R&D Expense | 77.1M | 84.3M | 100.5M | 112.1M | 126.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 283.7M | 290.5M | 356.4M | 351.5M | 337.2M |
| Selling & Marketing Expense | 751.3M | 822.9M | 1.1B | 1.2B | 1.2B |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 1.2B | 1.2B | 1.6B | 1.8B | 1.7B |
| Cost and Expenses | 1.9B | 2.0B | 2.4B | 2.6B | 2.5B |
| Operating Income (EBIT) | (315.4M) | (304.0M) | (312.3M) | 137.4M | (376.0M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (322.6M) | (311.7M) | (332.5M) | 132.3M | (392.1M) |
| Income Tax Expense | 30.3M | 23.6M | 2.2M | 41.0M | 57.7M |
| Bottom Line | |||||
| Net Income | (349.7M) | (329.6M) | (317.2M) | 103.4M | (437.9M) |
| Earnings from Cont. Ops | (352.9M) | (335.3M) | (334.7M) | 91.4M | (449.7M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (349.7M) | (329.6M) | (317.2M) | 103.4M | (437.9M) |
| Per Share | |||||
| Basic EPS | (CN¥0.45) | (CN¥0.42) | (CN¥0.40) | CN¥0.13 | (CN¥0.55) |
| Diluted EPS | (CN¥0.45) | (CN¥0.42) | (CN¥0.40) | CN¥0.13 | (CN¥0.55) |
| Revenue Per Share | CN¥2.21 | CN¥2.37 | CN¥2.76 | CN¥3.57 | CN¥3.45 |
| Shares | |||||
| Basic Shares Outstanding | 777.0M | 784.7M | 789.1M | 789.3M | 793.2M |
| Diluted Shares Outstanding | 777.0M | 784.7M | 789.1M | 789.3M | 793.2M |
| Profitability Metrics | |||||
| EBITDA | — | (118.2M) | (94.0M) | 357.1M | (157.1M) |
| D&A | — | 185.8M | 218.2M | 219.8M | 218.9M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026